Baicheng Pharmaceutical announced that its wholly-owned subsidiary Zhejiang Symer Pharmaceutical Co., Ltd. recently received a drug registration certificate approved and issued by the State Drug Administration. The drug is a Class 2.2 improved new drug levetiracetam sustained-release granules, which are suitable for adjuvant treatment of partial seizures in patients with epilepsy aged 12 and above. Compared to the marketed dosage form, these extended-release granules are more suitable for children and patients with swallowing difficulties. Currently, the drug has not been sold. It has been approved for production and sale or is affected by uncertainties, and will not have a significant impact on the company's recent performance.

Baicheng Pharmaceutical announced that its wholly-owned subsidiary Zhejiang Symer Pharmaceutical Co., Ltd. recently received a drug registration certificate approved and issued by the State Drug Administration. The drug is a Class 2.2 improved new drug levetiracetam sustained-release granules, which are suitable for adjuvant treatment of partial seizures in patients with epilepsy aged 12 and above. Compared to the marketed dosage form, these extended-release granules are more suitable for children and patients with swallowing difficulties. Currently, the drug has not been sold. It has been approved for production and sale or is affected by uncertainties, and will not have a significant impact on the company's recent performance.